Paragon Care's Purchase of Somnotec to be Earnings Accretive by Up to 3% in 2026, Euroz Hartleys Says
MT Newswires Live
Oct 29
Paragon Care's (ASX:PGC) acquisition of healthcare distributor Somnotec will be accretive to earnings per share by around 2% to 3% in fiscal 2026 and 7% in 2027, Euroz Hartleys said in a note on Tuesday.
The medical devices supplier bought Singapore-based Somnotec for an enterprise value of about A$28.4 million.
The deal is projected to accelerate Paragon Care's expansion in Asia and boost its ability to cater to original equipment manufacturers in the region.
Euroz Hartleys kept its buy rating and raised price target to AU$0.61 from AU$0.60.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.